Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
RESEARCH TOOLSreports
PTX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.06
Previous CloseN/A
Volume766.17K
Average Volume (3M)1.69M
Market Cap
AU$47.85M
Enterprise ValueAU$31.89M
Total Cash (Recent Filing)AU$8.41M
Total Debt (Recent Filing)AU$34.27K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,040,264,500
10 Day Avg. Volume1,972,290
30 Day Avg. Volume1,693,308
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.06 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$47.85M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Sep 01, 2025 which is in 12 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Feb 20, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,040,264,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$65.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.14%
12-Months-Change
Fundamentals
Return on Equity
-36.95%
Trailing 12-Months
Asset Growth
-33.04%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited (PTX) is an Australian clinical-stage oncology company dedicated to the development of innovative cancer therapies. The company is primarily engaged in the research and development of targeted and cellular therapies, including CAR-T and targeted therapies, aimed at treating a variety of cancers. PTX is committed to advancing its clinical programs with a focus on personalized medicine, leveraging its proprietary platforms and strategic collaborations to address unmet medical needs in cancer treatment.
Technical Analysis
Ownership Overview
2.22% Insiders
―
Mutual Funds
― Other Institutional Investors
97.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---